Non-insulin Antidiabetics - Type 2 diabetes unlikely to develop into a switch market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-08-10

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor expects the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, benefiting market uptake of newly developed, efficacious therapies. A variety of novel, non-insulin antidiabetic agents are poised to become available to patients in the next decade, with two DPP-4 inhibitors likely to launch in 2007 and two GLP-1 agonists entering the market by 2010.


Scope

  • Assessment of the patient potential for developmental non-insulin agents in the type 2 diabetes setting of over the period 2006-15
  • Overview of the non-insulin antidiabetics R&D pipeline, with detailed information on the classes in development and comparator drugs
  • Commercial analysis of key compounds in development regarding their ability to satisfy key unmet needs, supported by the views of key opinion leaders
  • Sales forecasts for key late-stage developmental non-insulin antidiabetics in the seven major markets to 2015


    • Report Highlights
    The diabetes market is worthy of investment because of the endemic size of its patient pool which is set to grow further, and the nature of its unmet clinical needs. This situation is reflected in the R&D pipeline for non-insulin antidiabetics, comprising a diverse collection of 76 novel agents in clinical development.

    Datamonitor has identified five late-stage candidate drugs likely to be launched in the diabetes market within the next five years. These are the DPP-4 inhibitors Galvus and Januvia, the GLP-1 agonists Byetta LAR and liraglutide, the PPAR-gamma modulator metaglidasen. Apart from metaglidasen, all four agents have blockbuster potential.

    Despite the fact that pipeline products will impact the diabetes market greatly in the next five years, there are currently no agents in late-stage clinical development that are likely to fully replace current mainstays of antidiabetic therapy. Type 2 diabetes is therefore likely to remain an add-on market rather than develop into a switch market.


    Reasons to Purchase

  • Understand the key factors that will contribute to the success of the next generation of anti-diabetes drugs
  • View independent sales forecasts for products in late stage development for therapy of type 2 diabetes
  • Understand physician sentiment on clinical trial endpoints and late-stage candidate drugs for the diabetes market

    • Table of Contents

    Other users found this report page using the following search terms: diabetes mk0893 bi 1356 diabetes mechanism 2 2268 ave mk type

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.